Fig. 1 · Structure

Documents & Downloads

Allopurinol sodium

Cat. No. A10056 CAS 17795-21-0

xanthine oxidase inhibitor

Allopurinol is a structural isomer of hypoxanthine (a naturally occurring purine in the body) and is an inhibitor of the enzyme xanthine oxidase.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Allopurinol sodium Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Allopurinol sodium from 3 published references. In vitro models include cerebellar slice cultures; HepG2 cells. In vivo models include adult male Sprague-Dawley breeder rats.

Allopurinol sodium In Vitro Studies

In LPS-challenged cerebellar slice cultures, pretreatment with Allopurinol at 1 mM produced a significant ROS decrease compared with time-matched cultures stimulated with LPS. In HepG2 cells exposed to fructose, KHK expression was significantly up-regulated with fructose alone but not in the presence of Allopurinol at 100 µmol/L. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

ROS response in cerebellar slice cultures

Cell-based study · Cerebellar slice cultures [1]

Cerebellar slice cultures were pretreated with Allopurinol at 1 mM for 2 h before LPS stimulation for 24 h. Allopurinol-pretreated cultures showed a significant ROS decrease after LPS challenge compared with time-matched cultures stimulated with LPS.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ROS decrease as quantified by H2DCFDA assayReported result a significant ROS decrease as quantified by H2DCFDA assay in the cultures treated with allopurinol 1 mM after LPS challenge compared with time-matched cultures stimulated with LPS[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM
Exposure duration
pretreated for 2 h with allopurinol using two different concentrations (100 µM and 1 mM) and then stimulated with 15 µg/ml of LPS for 24 h
Method
pretreated
Co-treatment
Other interventions in this design: LPS 15 µg/ml. Compound effect isolated by the comparison: compared with time-matched cultures stimulated with LPS.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Allopurinol

The paper names Allopurinol without stating the salt or form; not verified as the sodium form supplied as A10056. No dose conversion or lot validation.

Materials and Methods > Animals and cerebellar organotypic cultures (S4); Results > The microglia activation inhibitors ethyl pyruvate and allopurinol decreased demyelination and axonal damage (S124, S125)

ROS decrease as quantified by H2DCFDA assay: ROS decrease as quantified by H2DCFDA assay; comparator: time-matched cultures stimulated with LPS — Results > The microglia activation inhibitors ethyl pyruvate and allopurinol decreased demyelination and axonal damage (S125)

KHK Expression in Fructose-Exposed HepG2 Cells

Cell-based study · HepG2 cells [2]

HepG2 cells were exposed to fructose at 5 mmol/L for 72 hours with or without Allopurinol at 100 µmol/L. Western blot analysis showed that KHK expression was significantly up-regulated by fructose alone but not in the presence of Allopurinol.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
KHK expression analyzed by western blotReported result HepG2 cells were exposed to fructose (5 mmol/L) for 72 hours in the presence or absence of allopurinol (100 µmol/L) and KHK expression analyzed by western blot. KHK expression was significantly up-regulated by fructose alone (p<0.01) but not in the presence of allopurinol.[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 µmol/L
Exposure duration
In experiments involving allopurinol, probenecid and C75 treatment, cells were pre-incubated with these compounds for 8 hours prior exposure to fructose or uric acid. HepG2 cells were exposed to fructose (5 mmol/L) for 72 hours in the presence or absence of allopurinol (100 µmol/L).
Method
cells were pre-incubated with these compounds
Co-treatment
Other interventions in this design: fructose 5 mmol/L. Compound effect isolated by the comparison: in the presence or absence of allopurinol.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Allopurinol

The paper names Allopurinol without stating the salt or form; not verified as the sodium form supplied as A10056. No dose conversion or lot validation.

Materials and Methods > Cell Culture and Silencing (S9); Results > Uric Acid Up-regulates KHK Expression in Human Hepatocytes Independently of Fructose (S81, S83)

KHK expression analyzed by western blot: KHK expression analyzed by western blot; comparator: fructose alone — Results > Uric Acid Up-regulates KHK Expression in Human Hepatocytes Independently of Fructose (S81, S83)

Allopurinol sodium In Vivo Studies

In adult male Sprague-Dawley breeder rats, liver weight represented 4.5% of total body weight with fructose plus Allopurinol, compared with 5.6% with fructose alone. In male Sprague-Dawley rats with STZ-induced diabetes, body weight in the group receiving Allopurinol at 10 mg/kg by gavage was 221.3 ± 4.3 g; diabetic rats treated with water served as the comparison group. [2,3]

Liver weight in fructose-treated rats

Animal study · Adult male Sprague-Dawley breeder rats [2]

Adult male Sprague-Dawley breeder rats received Allopurinol at 30 mg/kg in drinking water for 10 days. Liver weight represented 4.5% of body weight in rats given fructose plus Allopurinol, compared with 5.6% in rats given fructose alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Liver weight normalized to body weightLiver weight normalized to body weight 4.5%[2]

Conditions shared by the study groups

Route
in drinking water
Treatment course
for 10 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Allopurinol 30 mg/kgrats given fructose aloneAs a percentage of total body weight, the livers of control, fructose and fructose plus allopurinol rats were 4.5%, 5.6% and 4.5%, respectively (p<0.05; Figure 1B).[2]
Allopurinol 30 mg/kg
Model: Adult male Sprague-Dawley breeder rats
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Allopurinol

The paper names Allopurinol without stating the salt or form; not verified as the sodium form supplied as A10056. No dose conversion or lot validation.

Materials and Methods > Rat Experiments (S10); Results > Fructose-induced Liver Steatosis is Ameliorated by Lowering Intracellular Uric Acid (S47, S48, S50); Figure 1 legend (S133)

Liver weight normalized to body weight: Liver weight normalized to body weight; comparator: rats given fructose alone — Results > Fructose-induced Liver Steatosis is Ameliorated by Lowering Intracellular Uric Acid (S50); Figure 1 legend (S133)

Allopurinol 30 mg/kg · Results > Fructose-induced Liver Steatosis is Ameliorated by Lowering Intracellular Uric Acid (S47, S50)

Body Weight in Diabetic Rats

Animal study · Male Sprague-Dawley rats; STZ-induced diabetic rats; n = 8 [3]

Male Sprague-Dawley rats with STZ-induced diabetes received Allopurinol at 10 mg/kg by gavage. Body weight in the STZ plus Allopurinol group was 221.3 ± 4.3 g; the comparison group comprised diabetic rats treated with water.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Body weight(g)Body weight STZ + allopurinol (10 mg/kg): 221.3 ± 4.3 g[3]

Conditions shared by the study groups

Route
by gavage
Treatment course
started on 4th day after STZ injection by gavage once daily at 9∶00 a.m.–10∶00 a.m. for the subsequent 7 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Allopurinol 10 mg/kgdiabetic control treated with water221.3 ± 4.3 g***[3]
Allopurinol 10 mg/kg
Model: Male Sprague-Dawley rats; STZ-induced diabetic rats; n = 8
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Allopurinol

The paper names Allopurinol without stating the salt or form; not verified as the sodium form supplied as A10056. No dose conversion or lot validation.

Materials and Methods > Animals (S1); Materials and Methods > Experimental Design (S7, S11, S13); Results > Quercetin and Allopurinol Improve Renal Dysfunction and Hyperuricemia through Regulating Expression Levels of Renal Urate Transport-related Proteins in Stz-treated Rats (S86); Table 2 legend (S160); Table 2 (T2.h1, T2.r2, T2.r6)

Body weight(g): Body weight(g); comparator: diabetic control treated with water — Materials and Methods > Experimental Design (S11); Table 2 legend (S160); Table 2 (T2.h1, T2.r6)

Allopurinol 10 mg/kg · Materials and Methods > Experimental Design (S11, S13); Table 2 legend (S160); Table 2 (T2.h1, T2.r6)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 17795-21-0
Applications xanthine oxidase inhibitor
Formula C5H3N4NaO
Molecular Weight 158.09
Synonyms Lopurin; Zyloprim; Aloprim
SMILES
C1=NNC2=C1C(=NC=N2)[O-].[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 30 mg/mL (188.56 mM)
Water 30 mg/mL (188.56 mM)
Ethanol 2 mg/mL (12.57 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Allopurinol sodium Research References

  1. [1] di Penta A, Moreno B, Reix S, et al. Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS One (2013). PMID: 23431360 DOI: 10.1371/journal.pone.0054722 Source material
  2. [2] Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One (2012). PMID: 23112875 DOI: 10.1371/journal.pone.0047948 Source material
  3. [3] Wang C, Pan Y, Zhang QY, et al. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS One (2012). PMID: 22701621 DOI: 10.1371/journal.pone.0038285 Source material

Added to your cart

View Cart Checkout
Loading...